Sequence Variation in X-ray Cross Complimenting (XRCC4, XRCC5, XRCC6 and XRCC7) Genes and the Risk of Gastrointestinal Cancer in South-Western Maharashtra: A Hospital Based Case-Control Study.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2025-05-01 DOI:10.31557/APJCP.2025.26.5.1571

Madhavi Narayan Patil, Parixit Jayprakash Bhandurge, Sandeep Sambhajirao Kadam, Kailas Dhondibhau Datkhile

{"title":"Sequence Variation in X-ray Cross Complimenting (XRCC4, XRCC5, XRCC6 and XRCC7) Genes and the Risk of Gastrointestinal Cancer in South-Western Maharashtra: A Hospital Based Case-Control Study.","authors":"Madhavi Narayan Patil, Parixit Jayprakash Bhandurge, Sandeep Sambhajirao Kadam, Kailas Dhondibhau Datkhile","doi":"10.31557/APJCP.2025.26.5.1571","DOIUrl":null,"url":null,"abstract":"Objective: A number of X-ray repair cross complementing group (XRCC) genes are found to be involved in the DNA repair by the repair of single strand breaks (SSBs). Variation in these genes may lead to variation in DNA repair capacity, thereby increasing the genetic susceptibility to numerous human cancers. Among the known genetic polymorphisms of the DNA repair genes, there are many functional genetic variants have been identified in the XRCC genes particularly XRCC4, XRCC5, XRCC6 and XRCC7 that shows the positive association with the multiple cancers including cancers of GI tract. Therefore, in the present study, polymorphic variants of XRCC4, XRCC5, XRCC6 and XRCC7 were chosen to be studied in association with gastrointestinal cancer susceptibility in the south western Maharashtrian population. Methods: A total of 200 histologically confirmed cases of gastrointestinal cancer (GI) and 200 hospital-based controls were included in the study. The genotyping for XRCC4, XRCC5, XRCC6 and XRCC7 genes was carried out by polymerase chain reaction-restriction fragment length polymorphism.Results: We found that tobacco consumption in any form either smoking or chewing (OR = 4.03; 95% CI: 2.65-6.11) and alcohol drinking habit (OR = 4.45; CI: 2.15-9.22) is strongly associated with gastrointestinal cancer risk. Similarly, data analysis of cases and control group showed that XRCC4.2 G1394T is significantly associated with GI cancer risk. Our studies also revealed that fewer repeats (1R/1R, 0R/0R) of XRCC5 in the promoter region were found to be associated with the increased risk of GI cancer. In case of XRCC7 6721G>T our findings suggest a strong association with development of GI cancer risk in south-western Maharashtrian population. However, we did not find any association of polymorphic variants of XRCC4.1 cd247, XRCC4.5 Intron-7 and XRCC6 61C>G with GI cancer risk in the study population. However, multicentric studies with larger sample size are needed to substantiate the findings.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 5","pages":"1571-1579"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.5.1571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: A number of X-ray repair cross complementing group (XRCC) genes are found to be involved in the DNA repair by the repair of single strand breaks (SSBs). Variation in these genes may lead to variation in DNA repair capacity, thereby increasing the genetic susceptibility to numerous human cancers. Among the known genetic polymorphisms of the DNA repair genes, there are many functional genetic variants have been identified in the XRCC genes particularly XRCC4, XRCC5, XRCC6 and XRCC7 that shows the positive association with the multiple cancers including cancers of GI tract. Therefore, in the present study, polymorphic variants of XRCC4, XRCC5, XRCC6 and XRCC7 were chosen to be studied in association with gastrointestinal cancer susceptibility in the south western Maharashtrian population. Methods: A total of 200 histologically confirmed cases of gastrointestinal cancer (GI) and 200 hospital-based controls were included in the study. The genotyping for XRCC4, XRCC5, XRCC6 and XRCC7 genes was carried out by polymerase chain reaction-restriction fragment length polymorphism.

Results: We found that tobacco consumption in any form either smoking or chewing (OR = 4.03; 95% CI: 2.65-6.11) and alcohol drinking habit (OR = 4.45; CI: 2.15-9.22) is strongly associated with gastrointestinal cancer risk. Similarly, data analysis of cases and control group showed that XRCC4.2 G1394T is significantly associated with GI cancer risk. Our studies also revealed that fewer repeats (1R/1R, 0R/0R) of XRCC5 in the promoter region were found to be associated with the increased risk of GI cancer. In case of XRCC7 6721G>T our findings suggest a strong association with development of GI cancer risk in south-western Maharashtrian population. However, we did not find any association of polymorphic variants of XRCC4.1 cd247, XRCC4.5 Intron-7 and XRCC6 61C>G with GI cancer risk in the study population. However, multicentric studies with larger sample size are needed to substantiate the findings.

查看原文本刊更多论文

x射线交叉互补基因（XRCC4、XRCC5、XRCC6和XRCC7）序列变异与西南马哈拉施特拉邦胃肠癌风险：基于医院的病例对照研究

目的：发现一些x射线修复交叉互补组（XRCC）基因参与DNA单链断裂（SSBs）修复。这些基因的变异可能导致DNA修复能力的变异，从而增加对许多人类癌症的遗传易感性。在已知的DNA修复基因遗传多态性中，已经鉴定出XRCC基因的许多功能性遗传变异，特别是XRCC4、XRCC5、XRCC6和XRCC7与包括胃肠道癌症在内的多种癌症呈正相关。因此，在本研究中，我们选择XRCC4、XRCC5、XRCC6和XRCC7的多态性变异来研究与西南马哈拉施特拉邦人群胃肠道癌症易感性的关系。方法：选取组织学确诊的胃肠癌（GI）患者200例，对照200例。采用聚合酶链反应-限制性片段长度多态性对XRCC4、XRCC5、XRCC6和XRCC7基因进行分型。结果：我们发现任何形式的烟草消费，无论是吸烟还是咀嚼(or = 4.03；95% CI: 2.65-6.11)和饮酒习惯(OR = 4.45；CI: 2.15-9.22)与胃肠道癌症风险密切相关。同样，病例和对照组的数据分析显示，XRCC4.2 G1394T与GI癌风险显著相关。我们的研究还发现，启动子区域XRCC5重复次数较少（1R/1R, 0R/0R）与胃肠道癌风险增加有关。在XRCC7 6721G>的情况下，我们的研究结果表明，在马哈拉施特拉邦西南部人群中，XRCC7 6721G>与胃肠道癌症风险的发展有很强的关联。然而，在研究人群中，我们没有发现XRCC4.1 cd247、XRCC4.5内含子-7和XRCC6 61C>G多态性变异与GI癌风险的任何关联。然而，需要更大样本量的多中心研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.